- MeSH
- Acyclovir administration & dosage therapeutic use MeSH
- Child MeSH
- Herpes Simplex MeSH
- Herpesviridae Infections diagnosis etiology therapy MeSH
- Immunosuppression Therapy MeSH
- Humans MeSH
- Recurrence diagnosis etiology therapy MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Publication type
- Review MeSH
- MeSH
- Acyclovir analogs & derivatives administration & dosage adverse effects MeSH
- Antiviral Agents administration & dosage MeSH
- Child MeSH
- Adult MeSH
- Herpes Genitalis drug therapy MeSH
- Herpes Labialis drug therapy MeSH
- Herpes Simplex diagnosis drug therapy MeSH
- Herpes Zoster diagnosis drug therapy MeSH
- Humans MeSH
- Chickenpox drug therapy complications MeSH
- Recurrence MeSH
- Secondary Prevention MeSH
- Valine analogs & derivatives administration & dosage adverse effects MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- MeSH
- Acyclovir analogs & derivatives administration & dosage therapeutic use MeSH
- Antiviral Agents MeSH
- Herpes Labialis etiology drug therapy MeSH
- Ascorbic Acid administration & dosage therapeutic use MeSH
- Humans MeSH
- Zinc Oxide administration & dosage therapeutic use MeSH
- Recurrence etiology drug therapy MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
A lip cream with special propolis extract GH 2002 at a concentration of 0.5% (199 patients) was tested against aciclovir 5% (198 patients) in the treatment of episodes of herpes labialis under double-blind conditions. Upon inclusion, all patients were in the vesicular phase. Application was five times daily of approximately 0.2 g of cream to the entire upper and lower lip. The primary parameter was the difference in time between groups to complete encrustation or epithelization of the lesions. Secondary endpoints were the course of typical herpes symptoms (pain, burning and itching, tension and swelling), the global assessment of efficacy and the safety of application. The predefined clinical situation was reached after a (median) 3 days with propolis and 4 days with aciclovir (p < 0.0001). Significant differences in favor of propolis were also found for all secondary parameters. No allergic reactions, local irritations or other adverse events occurred.
- MeSH
- Acyclovir therapeutic use MeSH
- Antiviral Agents * therapeutic use MeSH
- Apitherapy methods MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Herpes Labialis * drug therapy MeSH
- Humans MeSH
- Propolis * therapeutic use MeSH
- Recurrence MeSH
- Lip MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
- Keywords
- valacyklovir,
- MeSH
- Acyclovir analogs & derivatives therapeutic use MeSH
- Stomatitis, Aphthous * diagnosis drug therapy immunology MeSH
- Diagnosis, Differential MeSH
- gamma-Globulins therapeutic use MeSH
- Immunoglobulin G * immunology MeSH
- Injections, Intramuscular MeSH
- Middle Aged MeSH
- Humans MeSH
- Recurrence MeSH
- Valine analogs & derivatives therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
